EUCTR2008-007155-27-IT进行中（未招募）不适用
A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients with Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy - ND
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ARQULE
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Each prospective subject must meet ALL of the following inclusion criteria in order to be eligible for this study: 1. Written informed consent granted prior to initiation of any study-specific screening procedures 2. 18 year of age or older 3. Histologically or cytologically confirmed HCC 4. Archival, fresh core needle biopsy or fine needle aspiration (FNA) tumor samples 5. Received at least one cycle of prior systemic therapy (at least 3 weeks for continuously administered drugs) and experienced radiographic disease progression or was unable to tolerate therapy. 6. Discontinued prior treatment for at least 4 weeks, or at least 2 weeks (14 days) if drug was administered continuously and orally (e.g. sorafenib or sunitinib), prior to the study randomization 7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤1 (Appendix 2) 8. Local or loco-regional therapy (i.e., surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed ≥4 weeks prior to randomization. 9. Measurable disease as defined by a modified version of the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (see section 9). Tumor lesions previously treated with local therapy should demonstrate clear dimensional increase by radiographic assessment in order to be selected as target lesion(s) at baseline. (Radiological assessment needs to be redone within 7 days prior to randomization if the pre-study AFP levels have worsened by more than 30% since the end of the prior systemic treatment) 10. Adequate bone marrow, liver, and renal functions at Pre-Study Visit, defined as:  Platelet count ≥ 60 ? 109/L  Hemoglobin ≥ 9.0 g/dL  Absolute neutrophil count (ANC) ≥1.5 ? 109/L  Total bilirubin ≤ 2 mg/dL  Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 5 ? upper limit of normal (ULN)  Serum creatinine ≤1.5 ? ULN  International normalized ratio (INR) 0.8 to 1.2 or ≤3 for patients receiving anticoagulant such as coumadin or heparin. Patients who are therapeutically anticoagulated are allowed to participate provided that no prior evidence of underlying abnormality exists in these parameters.  Albumin ≥ 2.8 g/dL 11. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. 12. Male and female subjects of child-bearing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after last investigational drug dose received.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. More than 1 prior systemic regimen 2. Child-Pugh B-C cirrhotic status (see appendix 4 for Child-Pugh Classification) 3. Previous or concurrent cancer that is distinct from HCC in primary site or histology, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1). Any cancer curatively treated >3 years prior to enrollment is permitted. 4. History of congestive heart failure defined as Class II to IV per New York Heart Association (NYHA) classification; active coronary artery disease (CAD); clinically significant bradycardia or other uncontrolled, cardiac arrhythmia defined as ≥ Grade 3 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, or uncontrolled hypertension; myocardial infarction occurring within 6 months prior to study entry (myocardial infarction occurring > 6 months prior to study entry is permitted). 5. Active clinically serious infections defined as ≥ Grade 3 according to NCI CTCAE, version 4.0. 6. Substance abuse, medical, psychological or social conditions that may, in the opinion of the Investigator, interfere with the patient s participation in the study or evaluation of the study results 7. Any condition that is unstable or which could jeopardize the safety of the patient and his/her protocol compliance 8. Known human immunodeficiency virus (HIV) infection 9. Pregnancy or breast-feeding. 10. History of liver transplant 11. Inability to swallow oral medications 12. Clinically significant gastrointestinal bleeding occurring ≤4 weeks prior to randomization.
研究者
相似试验
进行中（未招募）
1 期
A Randomized Controlled Phase 2 Trial of ARQ 197 inPatients with Unresectable Hepatocellular Carcinoma(HCC) Who Have Failed One Prior Systemic Therapynresectable hepatocellular carcinoma (HCC)MedDRA version: 14.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007155-27-BEArQule, Inc.99
进行中（未招募）
不适用
A Randomized Controlled Phase 2 Trial of ARQ 197 inPatients with Unresectable Hepatocellular Carcinoma(HCC) Who Have Failed One Prior Systemic Therapynresectable hepatocellular carcinoma (HCC)MedDRA version: 14.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007155-27-DEArQule, Inc.99
已完成
2 期
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic TherapyUnresectable Hepatocellular CarcinomaNCT00988741ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)107
进行中（未招募）
不适用
A Randomized Phase 2 Study of ARQ 197 versus Investigator’s Choice of Second-Line Chemotherapy in Patients with Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment with One Prior Chemotherapy RegimeEUCTR2007-004622-25-LVArQule Inc.338
未知
2 期
Phase II study of ARQ 197 monotherapyAdvanced/recurrent gastric cancerJPRN-jRCT2080221133Kyowa Hakko Kirin Co., Ltd.